Singapore, April 11, 2023 – Update on Detection of the latest SARS-CoV-2 Variant
Credo Diagnostics Biomedical Pte Ltd continues the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using BLASTn analysis comparing primers and probes of the assays involving SARS-CoV-2 virus detection to the sequences listed in GISAID from January 1st, 2023 to March 31st, 2023.
We are pleased to announce that our VitaPCR™ system is capable of detecting the Omicron XBB.1.9.1 and XBB.1.16 subvariants and our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the Omicron subvariant, XBB.1.9.1 and XBB.1.16.
*The SARS-CoV-2 RNA detection assays include:
． VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
． VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
． VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)
For more information, contact us at service@credodxbiomed.com.
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.